Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK Inhibitor Therapy Followed by Reduced Intensity Haploidentical Transplantation for Myelofibrosis
NCT04370301Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2021
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial in myelofibrosis (MF) and graft-versus-host disease (GVHD) (2 cohorts), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Probability of primary and secondary graft failure at 5 years. Started Feb 2021; status: recruiting.
02
Conditions
myelofibrosis (MF)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04370301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04370301.